Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745970 | 0.88 | CHRNB2 (0.46) | HTR6CHRNB2CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL6739874 | 0.86 | HTR6 (0.42) | HTR6CHRNB2CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL6741940 | 0.82 | HTR6 (0.40) | HTR6HTR1DHTR1BKCNH2MCHR1 | |
| SCHEMBL6742324 | 0.76 | HTR6 (0.45) | HTR6HTR1DHTR1B | |
| SCHEMBL6745791 | 0.76 | HTR6 (0.51) | HTR6HTR1DHTR1B | |
| SCHEMBL6743248 | 0.76 | HTR6 (0.51) | HTR6HTR1DHTR1B | |
| SCHEMBL6745125 | 0.76 | HTR6 (0.43) | HTR6HTR1DHTR1BKCNH2 | |
| SCHEMBL6948549 | 0.75 | HTR6 (0.44) | HTR6HTR1DHTR1B | |
| SCHEMBL6948541 | 0.75 | HTR6 (0.44) | HTR6HTR1DHTR1B | |
| SCHEMBL6744614 | 0.73 | HTR6 (0.47) | HTR6HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | HTR6 237/4885CHRNB2 50/4885CHRNB4 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.